Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) Return on Capital Employed (2023 - 2024)

Summit Therapeutics' Return on Capital Employed history spans 2 years, with the latest figure at 0.53% for Q4 2024.

  • For Q4 2024, Return on Capital Employed rose 267.0% year-over-year to 0.53%; the TTM value through Dec 2024 reached 0.53%, up 267.0%, while the annual FY2024 figure was 0.81%, 66.0% up from the prior year.
  • Return on Capital Employed reached 0.53% in Q4 2024 per SMMT's latest filing, up from 0.54% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.53% in Q4 2024 to a low of 5.2% in Q3 2023.